Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987 on ClinicalTrials.gov · last registry update 2022-01-19

An unusually large phase 3: 902 participants, more than double the 424 typical for the stage. The sponsor logged completion for 22 February 2020. Primary outcome, as filed: Change From Randomisation to Week 68 in Body Weight (%). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 902
Started: 2018-06-04
Primary completion: 2020-02-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Randomisation to Week 68 in Body Weight (%)

Conditions studied

Metabolism and Nutrition Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.